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During the recent years, the role of C-peptide, released from the pancreatic beta cell, in regulating microvascular blood ﬂow, has
received increasing attention. In type 1 diabetic patients, intravenous application of C-peptide in physiological concentrations was
shown to increase microvascular blood ﬂow, and to improve microvascular endothelial function and the endothelial release of NO.
C-peptide was shown to impact microvascular blood ﬂow by several interactive pathways, like stimulating Na
+K
+ATPase or the
endothelial release of NO. There is increasing evidence, that in patients with declining beta cell function, the lack of C-peptide
secretion might play a putative role in the development of microvascular blood ﬂow abnormalities, which go beyond the eﬀects of
declining insulin secretion or increased blood glucose levels.
Copyright © 2008 T. Forst et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Patients with diabetes mellitus type 1 present with an exten-
sive risk for microvascular complications like retinopathy,
nephropathy, and peripheral neuropathy. Although hyper-
glycemia is recognized as a major driver in the development
of these diabetic complications, the precise mechanism,
whereby diabetes precipitates these complications, is not
fully understood. Furthermore, also in type 1 diabetic
patients with good metabolic control, the risk for the
development of microvascular complications is reduced but
stillnotabolished.IntheDCCTtrial,type1diabeticpatients
with sustained C-peptide secretion showed a signiﬁcant
smaller risk for microvascular complications compared with
those patients totally lacking C-peptide secretion from the
beta cell [1]. In this study, even modest beta cell activity was
associated with a decrease in the incidence of microvascular
complications.
Regulation of vascular tone is a dynamic process,
regulated by a complex interaction of several balancing
and counterbalancing forces. The kinetics of postprandial
insulin, C-peptide, and blood glucose levels was shown to
interact in the regulation of microvascular blood ﬂow in
several tissues like the skin or the heart [2, 3]. Although it
is not possible to separate the beneﬁcial eﬀects of residual
C-peptide secretion from those of residual insulin secretion,
there is increasing evidence that C-peptide might play a
putative role in the physiology of microvascular blood ﬂow
regulation.
In type 1 diabetes mellitus, numerous functional alter-
ations in blood ﬂow could be observed early after beta cell
dysfunction has emerged [4, 5]. Early type 1 diabetes is char-
acterised by increased microvascular blood ﬂow, increased
shear stress, and tangential pressure on the microvascular
endothelium. In addition, increased leukocyte-endothelial
adhesion [6], increased blood viscosity [7, 8], and changes
in the haemodynamic properties of red blood cells [9,
10] further aﬀect microvascular blood ﬂow. These early
functional disturbances proceed structural alterations in the
vessel wall,including basementmembrane thickening as well
as arteriolar hyalinosis [11].
The role of vascular endothelium for micro- and
macrovascular blood ﬂow regulation has been extensively
investigated within the last decade [12, 13]. The endothelial
cells coat the internal lumen of the vessels and serve as an
interface between circulating blood cells and the vascular
smooth muscle cell. In addition to serve as a physical barrier
between the blood and the underlying smooth muscle cells,2 Experimental Diabetes Research
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Figure 1: Mechanism of endothelial nitric oxide synthesis with
stimulation of guanylcyclase in the vascular smooth muscle cell and
subsequent vasorelaxation.
the endothelial cell facilitates a complex array of signalling
between the vessel wall and the enclosed blood compart-
ment. There are several transmitters released from endothe-
lial cells like nitric oxide (NO), endothelin 1, prostaglandins,
thrombin, substance P, bradykinin, serotonin, and others
which impact the vascular tone [14, 15].
Nitric oxide was identiﬁed as the primary vasodilator
released from the endothelium [16]. As shown in Figure 1,
NO elicits vasodilatation through stimulation of endothelial
NO-synthase (eNOS), increasing the endothelial release of
NO and subsequent activation of the guanylcyclase in the
vascular smooth muscle cell [12, 17–19].
AsshowninFigure 2,theactivityofeNOScouldbestim-
ulated or suppressed by several signaling molecules, known
to be altered in patients with diabetes mellitus. Reduced
levels of circulating NO contribute to vascular injury by
facilitating platelet-vascular wall interaction, increasing the
adhesion of circulating monocytes to the endothelial surface,
and stimulation of vascular smooth muscle proliferation
[20]. Impaired endothelial function and a reduction in
endothelial NO release are early features of type 1 diabetes
and thought to be principal causes of morbidity and
mortality in these patients.
2. EFFECTS OF C-PEPTIDE ON NITRIC OXIDE (NO)
C-peptide was shown to signiﬁcantly enhance the release
of NO from bovine aortic endothelial cells (BAECs) in a
dose-dependent manner [21, 22]. The release of NO in
this study was dose dependent and already obtained within
the physiological range of 1–6nM. C-peptide increased the
intracellular Ca2+ concentration in BAEC (see Figure 3).
Since the endothelial eNOS is a Ca2+/calmodulin-regulated
enzyme [23], both the C-peptide-stimulated Ca2+ signal
and the NO release were abolished in Ca2+-free medium.
Therefore, the peptide is likely to stimulate eNOS activity by
facilitating an inﬂux of Ca2+ into BAEC.
The NO release from BAEC declined from 2–30 minutes
of incubation, indicating a desensitization of the potential
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Figure 2: Substrates known to activate or reduce the endothelial
nitric oxide synthase system.
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Figure 3: C-peptide induced calcium inﬂux into endothelial cells.
Eﬀect of C-peptide on the Ca2+ signal in endothelial cells loaded
withFluo-3.AdditionofC-peptidetobovineaorticendothelialcells
yielded in a signiﬁcant increase in ﬂuorescence (above), which was
not found in calcium free medium (b).T. Forst et al. 3
receptor, or the subsequent signalling cascade, which has
been also demonstrated for other peptide signals for
endothelial NO release [24]. In conclusion, C-peptide is able
to stimulate an inﬂux of Ca2+ into endothelial cell, thereby
activating the Ca2+-sensitive endothelial NO synthetase and
stimulating the release of NO from the endothelial cell.
In a study by Kitamura et al., C-peptide was shown
to stimulate NO production by enhancing the mitogen-
activated protein-kinase dependent transcription of
endothelial nitric synthase in aortic endothelial cells of
Wistar rats [25]. In this study, it was shown that C-peptide
increases NO release from aortic endothelial cells by
enhancing eNOS expression through an ERK-dependent
transcriptional pathway.
3. EFFECTS OF C-PEPTIDE ON ERYTHROCYTE
Na+K
+ ATPASE
Na+K+ATPase activity has been found to be attenuated in
various cell types under diabetic conditions [26–28]. It has
also been shown that hyperglycemia inhibits Na+K+ATPase
activity by an endothelium dependent mechanism [29].
Na+K+-ATPase is a plasma membrane-associated protein
complex, expressed in most eukaryotic cells. It couples the
energy released from the intracellular hydrolysis of ATP
to the transport of cellular ions, a major pathway for
the controlled translocation of sodium and potassium ions
across the cell membrane. Therefore, Na+K+-ATPase con-
trols directly or indirectly many essential cellular functions,
for example, cell volume, free calcium concentrations, and
membrane potential [30]. Although there are tissue speciﬁc
diﬀerences in the regulations of Na+K+-ATPase activity,
hyperglycemia and diabetes are predominantly characterized
by a decrease in ouabain-sensitive Na+K+-ATPase activity.
This would result in an increase in intracellular calcium
concentration and an increased vascular tone, promoting the
development of vascular complications in diabetes mellitus.
Na+K+ATPase activity is involved in vascular regulation
based on a complex interaction between Na+K+-pump-
activity and an endothelium dependent increase of NO
[31, 32]. On the other hand, NO and cyclic-GMP have
been shown to increase vascular Na+K+ATPase activity, with
subsequent vasorelaxation [33, 34].
In order to hypothesize the potential mechanism of C-
peptide activity, previous studies concerning Na+K+ATPase
activity in erythrocytes and renal tubular cells are of
considerable interest [9, 35, 36]. Ohtomo et al. were able to
show that the attenuated activity of Na+-K+-ATPase activity
in renal tubular segments of diabetic rats is restored by
C-peptide. On the other hand, an attenuation of Na+-K+-
ATPase activity has been demonstrated to correlate with
decreased erythrocyte deformability in type 1 diabetic
patients [9].
In a recent study, erythrocyte Na+K+ATPase activity
was found to be reduced in type 1 diabetic patients, while
in type 2 diabetic patients a wide range of individual
Na+K+ATPase activities was observed, presenting some
patients withverylow Na+K+ATPaseactivityandotherswith
an o r m a lN a +K+ATPase activity. It appeared that erythrocyte
Na+K+ATPase activity was signiﬁcantly lower in those type
2 diabetic patients treated with insulin compared with those
on oral treatment. Also in the former, Na+K+ATPase activity
was comparable to those in type 1 diabetic patients.
In an in vitro study by Djemli-Shiplolye et al., incubation
of erythrocytes from type 1 diabetic patients with C-peptide
normalized erythrocyte Na+K+ATPase activity [37]. In
another study, intravenous infusion of C-peptide was found
to improve erythrocyte Na+K+ATPase activity in type 1
diabetic patients [38].
4. EFFECT OF C-PEPTIDE ON RED
CELL DEFORMABILITY
Blood ﬂow in larger vessels is determined by the vessel
diameter, blood viscosity, and vessel length according to the
law of Hagen-Pouiseuille. In the capillary bed, especially
if the diameter of the vessel is below the diameter of the
erythrocytes, blood ﬂow is predominantly determined by
the viscosity and deformability of the erythrocytes. Thus,
reduced erythrocyte deformability will reduce blood ﬂow if
the capillary diameter and blood pressure remain constant
[39].
Several studies demonstrated that factors such as
decreased erythrocyte deformability, increased erythrocyte
aggregation,andincreasedcellmembranerigiditycontribute
to alterations in microvascular blood ﬂow in patients with
diabetes mellitus [7, 9, 10, 40–44].
Concerning the possible mechanism of reduced erythro-
cyte deformability, it is noteworthy that Na+-K+-ATPase
activity has been shown to be attenuated in several cell types,
including erythrocytes in diabetic patients [9, 35, 36], and
that it may be restored not only by insulin but C-peptide as
well [35].
The deformability of erythrocytes in type 1 diabetic
patients was found to be reduced compared to healthy
controls [22]. Both groups were matched concerning their
glucose levels in order to exclude a glucotoxic eﬀect.
Deformability was tested under physiological (0.3 to 10Pa)
and supraphysiological (>10Pa) shear stress rates by means
of laser diﬀractoscopy. Incubation of erythrocytes from
healthy controls and type 1 diabetic patients with diﬀerent
concentrations of C-peptide restored erythrocyte deforma-
bility in type 1 diabetic patients but was without any eﬀect in
erythrocytes of nondiabetic controls (see Figure 4).
It is speculative to discuss the underlying mechanism
basedupontheseresults,butimpairedNa+K+ATPase activity
may contribute to the decrease in erythrocyte deformability
by increasing the intracellular sodium concentration with
subsequent intracellular accumulation of free calcium ions
d u et oc o m p e t i t i o ni nt r a n s m e m b r a n o u se x c h a n g e[ 45].
These abnormalities in calcium homeostasis are known
to enhance spectrin dimer-dimer interaction and spectrin-
protein 4.1-actin interaction [46, 47]. The latter is being
promoted by adducin, a membrane-skeleton-associated
calmodulin-binding protein [48].
Pretreatment of erythrocytes from type 1 diabetic
patients with ouabain, EDTA, or pertussis toxin completely
abolished C-peptide eﬀects on erythrocyte deformability as4 Experimental Diabetes Research
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Figure 4: Representative analysis of erythrocyte deformability at
1.75Pa. This graph shows the alterations of elongation index E at
a shear stress of 1.75Pa, which is frequently achieved in vivo. C-
peptide did not modify the deformability of erythrocytes obtained
from healthy controls, whereas the deformability of diabetic
erythrocytes was restored to normal levels after administration
of diﬀerent concentrations of the peptide. Statistical analysis was
performed by Student’s t test.
shown in more detail in the paper of Hach et al. in the same
issue of Experimental Diabetes Research.
5. EFFECTS OF C-PEPTIDE ON MICROVASCULAR
BLOOD FLOW
In several studies, C-peptide was shown to aﬀect microvas-
cular blood ﬂow and to improve nerve or renal function
in animal models of type 1 diabetes and in humans with
type 1 diabetes mellitus [49–52]. In a study by Lindstrom
et al., C-peptide supplementation was shown to increase
microvascular blood ﬂow and to enhance the recruitment
of capillaries in isolated kidneys of the rat [53]. In another
study, the eﬀect of C-peptides was investigated in skeletal
muscle arterioles isolated from rat cremaster muscles [54].
In this study, C-peptide evoked a concentration independent
arteriolar dilatation in a range between 0.3 and 1000ng/mL.
Addition of insulin at low concentrations, which had no
vascular eﬀect by its own, enhanced the vascular eﬀect of
C-peptide, indicating a permissive role of both pancreatic
peptides in the regulation of microvascular blood ﬂow.
Inhibition of the nitric oxide synthase by LNMA completely
abolished the vasodilating response to C-peptide, further
stressing the role of NO in the transmission of C-peptide
vascular eﬀects.
In a study done by Ido et al., beneﬁcial eﬀects of C-
peptide supplementation could be documented in several
vascularbedsindiabeticrats[55].Intheirstudy,biosynthetic
human C-peptide was given subcutaneously twice daily for
5 weeks in control rats and streptozotocin-induced diabetic
rats. Highly supraphysiological peak plasma C-peptide levels
between 9 and 10nM were reached. C-peptide markedly
reduced the diabetes induced increase in blood ﬂow in
the anterior uvea, retina, and sciatic nerve. In addition, C-
peptide prevented increased 125I-labeled albumin perme-
ation in retina, nerve, and in the aorta. The eﬀect on
microvascular blood ﬂow was accompanied by an increase
in caudal motor nerve conduction velocity. No eﬀect of
C-peptide, neither on microvascular blood ﬂow nor on
motor nerve conduction velocity, could be observed in the
healthy control rats. Cotter et al. observed the vascular
eﬀects of C-peptide on sciatic endoneurial blood ﬂow in
streptozotocin diabetic rats at physiological C-peptide con-
centrations [49]. In their study, C-peptide supplementation
revealed an improvement in endoneurial blood ﬂow and
vascular conductance by 57 and 66%, respectively. The
increase in endoneurial blood ﬂow was accompanied by an
improvement in motor nerve conduction velocity by 62%
and in sensory nerve conduction velocity by 78%. Again,
treatment with L-NNA abolished the eﬀect of C-peptide on
endoneurial blood ﬂow and nerve conduction velocity.
In an investigation by Johanssen et al., the eﬀect of C-
peptides on skeletal muscle blood ﬂow was observed in
type 1 diabetic patients and in healthy controls during
exercise [56]. In the type 1 diabetic subjects, blood ﬂow
and capillary diﬀusion capacity of the exercising forearm
at baseline were approximately 30% lower compared to the
healthy control subjects. Intravenous administration of C-
peptide increased forearm blood ﬂow by 27% and capillary
diﬀusion capacity by 52% to levels similar to those observed
in the healthy controls. No signiﬁcant changes in blood
ﬂow could be observed in healthy controls receiving C-
peptide or in diabetic patients receiving placebo infusion. In
accordancewiththeobservedimprovementsinmuscleblood
ﬂow, forearm oxygen and glucose uptake increased markedly
after C-peptide administration in type 1 diabetic patients.
Skin blood ﬂow is aﬀected early after the diagnosis of
diabetes mellitus [57–59]. The skin capillary circulation is
functionally situated in parallel to the arteriovenous shunts
and is thought to have the primary function of tissue nutri-
tion. It has been estimated that 80–90% of total skin blood
ﬂow passes through thermoregulatory arteriovenous shunts
and does not enter the nutritive part of the capillary bed
[60–62]. While total skin perfusion is increased in diabetes
mellitus, nutritional capillary skin blood ﬂow was shown to
be reduced in diabetic patients [60, 61, 63]. As shown in
Figure 5, short-term infusion of C-peptide in type 1 diabetic
patients was found to redistribute microvascular blood ﬂow
from the subpapillary thermoregulatory blood ﬂow into the
nutritive capillary bed [64]. At baseline, nutritive capillary
blood ﬂow was signiﬁcantly lower in type 1 diabetic patients
compared with the control group. C-peptide supplementa-
tion in type 1 diabetic patients increased capillary blood
ﬂow to a level comparable to that observed in the healthy
control group. Thirty minutes after the termination of the
C-peptide infusion, capillary blood ﬂow had declined to a
level not diﬀerent from baseline levels. No such eﬀect of C-
peptide application on microvascular skin blood ﬂow could
be observed in nondiabetic subjects. A linear relationship
was found between plasma C-peptide levels and the capillary
blood ﬂow velocity (r = 0.401; P<. 0001).T. Forst et al. 5
Fernqvist-Forbes et al. studied the eﬀect of C-peptide
on ﬂow-mediated vasodilatation (FMD) in type 1 diabetic
patients [65]. In addition, the arterial dilatation to glyceryl
trinitrate, which is an endothelium independent marker
of vascular smooth muscle function, was investigated.
When compared with the healthy control group, the type
1 diabetic patients revealed a lower FMD. Following C-
peptide administration, blood ﬂow in the brachial artery
increased by approximately 35%, and FMD was signiﬁcantly
improved. No eﬀect of C-peptide could be observed on the
microvascular response to glyceryl trinitrate, which further
conﬁrm the endothelium dependent pathway of C-peptide.
As shown in Figure 1, acetylcholine elicits vasodilatation
through a stimulation of endothelial NO-synthase (eNOS)
with an increase in the endothelial release of NO and a
subsequent stimulation of the guanylcyclase in the vascular
smooth muscle cell. In a recent study, the eﬀect of intra-
venous C-peptide infusion on the acetylcholine induced
increase in microvascular blood ﬂow was investigated in type
1 diabetic patients [38]. Skin microvascular response was
measured by laser Doppler ﬂuxmetry, and acetylcholine was
applied to the dorsum of the foot using the technique of
iontophoresis. The microvascular response to acetylcholine
increased by 133% during short-term infusion of C-peptide,
which was accompanied by a signiﬁcant increase in plasma
cyclic GMP levels (see Figure 6).
In contrast, in a study of Polska et al., no eﬀect of C-
peptide supplementation in type 1 diabetic patients could be
observed on retinal blood ﬂow [66].
Therefore, it could be postulated that C-peptide aﬀects
microvascular blood ﬂow in a tissue speciﬁc manner.
6. CONCLUSIONS
Insulin depletion in type 1 diabetic patients results in hyper-
glycaemia and the development of vascular complications of
diabetes mellitus. Treatment of type 1 diabetes mellitus with
insulin replacementis aneﬀectivetoolforaddressing glucose
metabolism, but it seems conceivable that the loss of C-
peptide secretion frompancreatic beta cellsmightcontribute
to the vascular complications in patients with diabetes
mellitus type 1. As shown in this review, recent studies
showed that C-peptide is biologically active by modulating
endothelial function and microvascular blood ﬂow. The
underlying mechanisms involve the activation of endothelial
nitric oxide synthase and the activation of Na+K+ATPase,
which was shown to be calcium-dependent and ouabain
sensitive. The postulated mechanism by which C-peptide
interact with microvascular blood ﬂow is illustrated in
Figure 7.
Since the vascular eﬀects of C-peptide could not be
conﬁrmed in all tissues, it seems conceivable that there
are tissue speciﬁc diﬀerences in the mode of C-peptides
vascular activities. Instead a speciﬁc binding of C-peptide
to the cell membrane could be demonstrated [67], no
speciﬁcreceptorforC-peptidecouldbeisolatedneitherfrom
endothelialcellsnorfromothercellsystems.Therefore,there
is still a substantial need for the further investigation of the
molecular eﬀects of C-peptide on cellular level.
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Figure 7: Schematic presentation of the molecular mechanism of
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Nevertheless, the improvement in erythrocyte ﬂexibility
and microvascular blood ﬂow after C-peptide supplemen-
tation in type 1 diabetic patients encourages the claim6 Experimental Diabetes Research
for further prospective interventional trials to establish the
clinical relevance for C-peptide supplementation in type 1
diabetic patients.
REFERENCES
[1] M. W. Steﬀes, S. Sibley, M. Jackson, and W. Thomas, “β-cell
function and the development of diabetes-related complica-
tions in the diabetes control and complications trial,” Diabetes
Care, vol. 26, no. 3, pp. 832–836, 2003.
[2] R. Scognamiglio, C. Negut, S. V. De Kreutzenberg, A.
Tiengo, and A. Avogaro, “Postprandial myocardial perfusion
inhealthysubjectsandintype2diabeticpatients,”Circulation,
vol. 112, no. 2, pp. 179–184, 2005.
[3] T. Forst, S. Forst, K. Strunk, et al., “Impact of insulin on
microvascular blood ﬂow and endothelial cell function in the
postprandial state in patients with type 1 diabetes,” Journal
of Diabetes and Its Complications, vol. 19, no. 3, pp. 128–132,
2005.
[4] E. Tibiric ¸´ a, E. Rodrigues, R. A. Cobas, and M. B. Gomes,
“Endothelial function in patients with type 1 diabetes eval-
uated by skin capillary recruitment,” Microvascular Research,
vol. 73, no. 2, pp. 107–112, 2007.
[ 5 ]T .F o r s t ,A .P f ¨ utzner, T. Kunt, et al., “Skin microcirculation
in patients with type I diabetes with and without neuropathy
after neurovascular stimulation,” Clinical Science, vol. 94, no.
3, pp. 255–261, 1998.
[6] T. Kunt, T. Forst, O. Harzer, et al., “The inﬂuence of advanced
glycation endproducts (AGE) on the expression of human
endothelial adhesion molecules,” Experimental and Clinical
Endocrinology and Diabetes, vol. 106, no. 3, pp. 183–188, 1998.
[7] E. Ernst and A. Matrai, “Altered red and white blood cell
rheology in type II diabetes,” Diabetes, vol. 35, no. 12, pp.
1412–1415, 1986.
[8] A. J. Barnes, P. Locke, P. R. Scudder, T. L. Dormandy, J.
A. Dormandy, and J. Slack, “Is hyperviscosity a treatable
component of diabetic microcirculatory disease?” The Lancet,
vol. 2, no. 8042, pp. 789–791, 1977.
[9] P. Finotti and P. Palatini, “Reduction of erythrocyte (Na
+-
K
+)ATPaseactivityintype1(insulin-dependent)diabeticsub-
jects and its activation by homologous plasma,” Diabetologia,
vol. 29, no. 9, pp. 623–628, 1986.
[ 1 0 ]D .E .M c M i l l a n ,N .G .U t t e r b a c k ,a n dJ .L aP u m a ,“ R e d u c e d
erythrocyte deformability in diabetes,” Diabetes, vol. 27, no. 9,
pp. 895–901, 1978.
[11] J. E. Tooke, “Microvascular function in human diabetes: a
physiological perspective,” Diabetes, vol. 44, no. 7, pp. 721–
726, 1995.
[12] J. Calles-Escandon and M. Cipolla, “Diabetes and endothelial
dysfunction:aclinical perspective,” Endocrine Reviews,vol. 22,
no. 1, pp. 36–52, 2001.
[13] L. Kuo, M. J. Davis, and W. M. Chilian, “Myogenic activity
in isolated subepicardial and subendocardial coronary arte-
rioles,” American Journal of Physiology, vol. 255, no. 6, pp.
H1558–H1562, 1988.
[14] J. A. Colwell and M. F. Lopes-Virella, “A review of the
development of large-vessel disease in diabetes mellitus,”
American Journal of Medicine, vol. 85, no. 5, supplement 1, pp.
113–118, 1988.
[15] R. F. Furchgott and J. V. Zawadzki, “The obligatory role of
endothelial cells in the relaxation of arterial smooth muscle by
acetylcholine,” Nature, vol. 288, no. 5789, pp. 373–376, 1980.
[16] R. M. J. Palmer, A. G. Ferrige, and S. Moncada, “Nitric oxide
release accounts for the biological activity of endothelium-
derived relaxing factor,” Nature, vol. 327, no. 6122, pp. 524–
526, 1987.
[17] S.J.Morris,A.C.Shore,andJ.E.Tooke,“Responsesoftheskin
microcirculationtoacetylcholineandsodiumnitroprussidein
patientswithNIDDM,”Diabetologia,vol.38,no.11,pp.1337–
1344, 1995.
[18] G. M. Pieper, W. Siebeneich, G. Moore-Milton, and A.
M. Roza, “Reversal by L-arginine of a dysfunctional argi-
nine/nitric oxide pathway in the endothelium of the genetic
diabetic BB rat,” Diabetologia, vol. 40, no. 8, pp. 910–915,
1997.
[19] P. G. McNally, P. A. C. Watt, T. Rimmer, A. C. Burden, J.
R. Hearnshaw, and H. Thurston, “Impaired contraction and
endothelium-dependent relaxation in isolated resistance ves-
sels from patients with insulin-dependent diabetes mellitus,”
Clinical Science, vol. 87, no. 1, pp. 31–36, 1994.
[ 2 0 ]M .T .J o h n s t o n e ,S .J .C r e a g e r ,K .M .S c a l e s ,J .A .C u s c o ,
B. K. Lee, and M. A. Creager, “Impaired endothelium-
dependent vasodilation in patients with insulin-dependent
diabetes mellitus,” Circulation, vol. 88, no. 6, pp. 2510–2516,
1993.
[ 2 1 ] T .W a l l e r a t h ,T .K u n t ,T .F o r s t ,e ta l . ,“ S t i m u l a t i o no f
endothelial nitric oxide synthase by proinsulin C-peptide,”
Nitric Oxide, vol. 9, no. 2, pp. 95–102, 2003.
[22] T. Kunt, S. Schneider, A. Pf¨ utzner, et al., “The eﬀe c to fh u m a n
proinsulin C-peptide on erythrocyte deformability in patients
with type I diabetes mellitus,” Diabetologia,v o l .4 2 ,n o .4 ,p p .
465–471, 1999.
[23] U. F¨ orstermann, J. S. Pollock, H. H. Schmidt, M. Heller,
and F. Murad, “Calmodulin-dependent endothelium-derived
relaxing factor/nitric oxide synthase activity is present in the
particulate and cytosolic fractions of bovine aortic endothelial
cells,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 88, no. 5, pp. 1788–1792, 1991.
[24] U. F¨ orstermann, A. Mugge, U. Alheid, A. Haverich, and J.
C. Frolich, “Selective attenuation of endothelium-mediated
vasodilation in atherosclerotic human coronary arteries,”
Circulation Research, vol. 62, no. 2, pp. 185–190, 1988.
[25] T. Kitamura, K. Kimura, B. D. Jung, et al., “Proinsulin C-
peptide activates cAMP response element-binding proteins
through the p38 mitogen-activated protein kinase pathway in
mouse lung capillary endothelial cells,” Biochemical Journal,
vol. 366, no. 3, pp. 737–744, 2002.
[26] H. Wald, P. Scherzer, R. Rasch, and M. M. Popovtzer, “Renal
tubular Na
+-K
+-ATPase in diabetes mellitus: relationship to
metabolic abnormality,” American Journal of Physiology, vol.
265, no. 1, pp. E96–E101, 1993.
[27] A. Gerbi, O. Barbey, D. Raccah, et al., “Alteration of Na,K-
ATPase isoenzymes in diabetic cardiomyopathy: eﬀect of
dietary supplementation with ﬁsh oil (n-3 fatty acids) in rats,”
Diabetologia, vol. 40, no. 5, pp. 505, 1997.
[28] P. Vague, D. Dufayet, T. Coste, C. Moriscot, M. F. Jannot,
and D. Raccah, “Association of diabetic neuropathy with Na/K
ATPase gene polymorphism,” Diabetologia, vol. 40, no. 5, pp.
506–511, 1997.
[29] D. A. Simmons, E. F. Kern, A. I. Winegrad, and D. B. Martin,
“Basal phosphatidylinositol turnover controls aortic Na
+/K
+
ATPase activity,” The Journal of Clinical Investigation, vol. 77,
no. 2, pp. 503–513, 1986.
[30] A. M. Rose and R. Valdes Jr., “Understanding the sodium
pump and its relevance to disease,” Clinical Chemistry, vol. 40,
no. 9, pp. 1674–1685, 1994.T. Forst et al. 7
[ 3 1 ]R .M .R a p o p o r t ,K .S c h w a r t z ,a n dF .M u r a d ,“ E ﬀects of
Na
+,K
+-pump inhibitors and membrane depolarizing agents
on acetylcholine-induced endothelium-dependent relaxation
and cyclic GMP accumulation in rat aorta,” European Journal
of Pharmacology, vol. 110, no. 2, pp. 203–209, 1985.
[ 3 2 ]C .J .J .T a c k ,J .A .L u t t e r m a n ,G .V e r v o o r t ,T .T h i e n ,a n dP .
Smits,“Activationofthesodium-potassiumpumpcontributes
toinsulin-inducedvasodilationinhumans,”Hypertension,vol.
28, no. 3, pp. 426–432, 1996.
[33] S. Gupta, C. McArthur, C. Grady, and N. B. Ruderman,
“Stimulation of vascular Na
+-K
+-ATPase activity by nitric
oxide: a cGMP-independent eﬀect,” American Journal of
Physiology, vol. 266, no. 5, pp. H2146–H2151, 1994.
[34] V. E. Rand and C. J. Garland, “Endothelium-dependent
relaxation to acetylcholine in the rabbit basilar artery: impor-
t a n c eo fm e m b r a n eh y p e r p o l a r i z a t i o n , ”British Journal of
Pharmacology, vol. 106, no. 1, pp. 143–150, 1992.
[35] Y. Ohtomo, A. Aperia, B. Sahlgren, B.-L. Johansson, and
J. Wahren, “C-peptide stimulates rat renal tubular Na
+,K
+-
ATPase activity in synergism with neuropeptide Y,” Diabetolo-
gia, vol. 39, no. 2, pp. 199–205, 1996.
[36] Y. Ohtomo, T. Bergman, B.-L. Johansson, H. J¨ ornvall, and
J. Wahren, “Diﬀerential eﬀects of proinsulin C-peptide frag-
ments on Na
+,K
+-ATPase activity of renal tubule segments,”
Diabetologia, vol. 41, no. 3, pp. 287–291, 1998.
[37] A. Djemli-Shipkolye, P. Gallice, T. Coste, et al., “The eﬀects ex
vivo and in vitro of insulin and C-peptide on Na/K adenosine
triphosphatase activity in red blood cell membranes of type
1 diabetic patients,” Metabolism, vol. 49, no. 7, pp. 868–872,
2000.
[38] T. Forst, D. Dufayet De La Tour, T. Kunt, et al., “Eﬀects of
proinsulin C-peptide on nitric oxide, microvascular blood
ﬂow and erythrocyte Na
+,K
+-ATPase activity in diabetes
mellitus type I,” Clinical Science, vol. 98, no. 3, pp. 283–290,
2000.
[39] S. Chien, “Red cell deformability and its relevance to blood
ﬂow,” Annual Review of Physiology, vol. 49, pp. 177–192, 1987.
[40] D. Bareford, P. E. Jennings, P. C. Stone, S. Baar, A. H. Barnett,
and J. Stuart, “Eﬀects of hyperglycaemia and sorbitol accu-
mulation on erythrocyte deformability in diabetes mellitus,”
Journal of Clinical Pathology, vol. 39, no. 7, pp. 722–727, 1986.
[41] K. Chimori, S. Miyazaki, J. Kosaka, A. Sakanaka, Y. Yasuda,
and K. Miura, “Increased sodium inﬂux into erythrocytes in
diabetesmellitusandhypertension,”ClinicalandExperimental
Hypertension, vol. 8, no. 2, pp. 185–199, 1986.
[42] N. S. Cohen, J. E. Ekholm, M. G. Luthra, and D. J. Hanahan,
“Biochemical characterization of density separated human
erythrocytes,” Biochimica et Biophysica Acta, vol. 419, no. 2,
pp. 229–242, 1976.
[43] Y. Baba, M. Kai, T. Kamada, S. Setoyama, and S. Otsuji,
“Higher levels of erythrocyte membrane microviscosity in
diabetes,” Diabetes, vol. 28, no. 12, pp. 1138–1140, 1979.
[44] H. Schmid-Sch¨ onbein and E. Volger, “Red-cell aggregation
and red-cell deformability in diabetes,” Diabetes, vol. 25,
supplement 2, pp. 897–902, 1976.
[45] L. Mazzanti, R. A. Rabini, E. Faloia, P. Fumelli, E. Bertoil,
and R. De Pirro, “Altered cellular Ca
2+ and Na
+ transport in
diabetes mellitus,” Diabetes, vol. 39, no. 7, pp. 850–854, 1990.
[46] Y. Takakuwa and N. Mohandas, “Modulation of erythrocyte
membrane material properties by Ca
2+ and calmodulin.
Implications for their role in regulation of skeletal protein
interactions,” The Journal of Clinical Investigation, vol. 82, no.
2, pp. 394–400, 1988.
[47] P. O. Schischmanoﬀ, R. Winardi, D. E. Discher, et al.,
“Deﬁning of the minimal domain of protein 4.1 involved in
spectrin-actin binding,” Journal of Biological Chemistry, vol.
270, no. 36, pp. 21243–21250, 1995.
[48] K. Gardner and V. Bennett, “A new erythrocyte membrane-
associated protein with calmodulin binding activity. Identiﬁ-
cation and puriﬁcation,” Journal of Biological Chemistry, vol.
261, no. 3, pp. 1339–1348, 1986.
[49] M. A. Cotter, K. Ekberg, J. Wahren, and N. E. Cameron,
“Eﬀects of proinsulin C-peptide in experimental diabetic
neuropathy: vascular actions and modulation by nitric oxide
synthase inhibition,” Diabetes, vol. 52, no. 7, pp. 1812–1817,
2003.
[50] H. Kamiya, W. Zhang, K. Ekberg, J. Wahren, and A. A. F.
Sima, “C-peptide reverses nociceptive neuropathy in type 1
diabetes,” Diabetes, vol. 55, no. 12, pp. 3581–3587, 2006.
[51] B.-L. Johansson, K. Borg, E. Fernqvist-Forbes, A. Kernell, T.
Odergren, and J. Wahren, “Beneﬁcial eﬀects of C-peptide on
incipient nephropathy and neuropathy in patients with type 1
diabetes mellitus,” Diabetic Medicine, vol. 17, no. 3, pp. 181–
189, 2000.
[52] K. Ekberg, L. Juntti-Berggren, A. Norrby, et al., “C-peptide
improves sensory nerve function in type 1 diabetes and
neuropathy,”Diabetologia,vol.48,supplement1,p.A81,2005.
[53] K. Lindstr¨ om, C. Johansson, E. Johnsson, and B. Haraldsson,
“Acute eﬀects ofC-peptideonthemicrovasculature ofisolated
perfusedskeletalmusclesandkidneysinrat,”Acta Physiologica
Scandinavica, vol. 156, no. 1, pp. 19–25, 1996.
[54] M. E. Jensen and E. J. Messina, “C-peptide induces a
concentration-dependent dilation of skeletal muscle arterioles
only in presence of insulin,” American Journal of Physiology,
vol. 276, no. 4 45-4, pp. H1223–H1228, 1999.
[55] Y. Ido, A. Vindigni, K. Chang, et al., “Prevention of vascular
and neural dysfunction in diabetic rats by C-peptide,” Science,
vol. 277, no. 5325, pp. 563–566, 1997.
[56] B.-L. Johansson, B. Linde, and J. Wahren, “Eﬀects of C-
peptideonbloodﬂow,capillarydiﬀusioncapacityandglucose
utilization in the exercising forearm of type 1 (insulin-
dependent)diabeticpatients,”Diabetologia,vol.35,no.12,pp.
1151–1158, 1992.
[57] J. E. Tooke, P. E. Lins, J. Ostergren, and B. Fagrell, “Skin
microvascular autoregulatory responses in type I diabetes: the
inﬂuence of duration and control,” International Journal of
Microcirculation, Clinical and Experimental,v o l .4 ,n o .3 ,p p .
249–256, 1985.
[58] U. Ewald, T. Tuvemo, and G. Rooth, “Early reduction of vas-
cularreactivityindiabeticchildrendetectedbytranscutaneous
oxygen electrode,” The Lancet, vol. 1, no. 8233, pp. 1287–1288,
1981.
[59] M. D. Flynn and J. E. Tooke, “Aetiology of diabetic foot
ulceration:aroleforthemicrocirculation?”DiabeticMedicine,
vol. 9, no. 4, pp. 320–329, 1992.
[60] G. J¨ orneskog, K. Brismar, and B. Fagrell, “Skin capillary
circulation is more impaired in the toes of diabetic than non-
diabetic patients with peripheral vascular disease,” Diabetic
Medicine, vol. 12, no. 1, pp. 36–41, 1995.
[61] G. J¨ orneskog, K. Brismar, and B. Fagrell, “Skin capillary
circulation severely impaired in toes of patients with IDDM,
with and without late diabetic complications,” Diabetologia,
vol. 38, no. 4, pp. 474–480, 1995.
[62] A. J. M. Boulton, J. H. B. Scarpello, and J. D. Ward, “Venous
oxygenation in the diabetic neuropathic foot: evidence of
arteriovenous shunting?” Diabetologia, vol. 22, no. 1, pp. 6–8,
1982.8 Experimental Diabetes Research
[63] G. J¨ o r n e s k o g ,J .O s t e r g r e n ,G .T y d e n ,J .B o l i n d e r ,a n dB .
Fagrell, “Does combined kidney and pancreas transplanta-
tion reverse functional diabetic microangiopathy?” Transplant
International, vol. 3, no. 3, pp. 167–170, 1990.
[64] T. Forst, T. Kunt, T. Pohlmann, et al., “Biological activity
of C-peptide on the skin microcirculation in patients with
insulin-dependent diabetes mellitus,” The Journal of Clinical
Investigation, vol. 101, no. 10, pp. 2036–2041, 1998.
[65] E. Fernqvist-Forbes, B.-L. Johansson, and M. J. Eriksson,
“Eﬀects of C-peptide on forearm blood ﬂow and brachial
arterydilatationinpatientswithtype1diabetesmellitus,”Acta
Physiologica Scandinavica, vol. 172, no. 3, pp. 159–165, 2001.
[66] E. Polska, J. Kolodjaschna, F. Berisha, et al., “C-peptide does
not aﬀect ocular blood ﬂow in patients with type 1 diabetes,”
Diabetes Care, vol. 29, no. 9, pp. 2034–2038, 2006.
[67] R. Rigler, A. Pramanik, P. Jonasson, et al., “Speciﬁc binding of
proinsulin C-peptide to human cell membranes,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 96, no. 23, pp. 13318–13323, 1999.